Online inquiry

IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5125MR)

This product GTTS-WQ5125MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL1RAP gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001167928.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3556
UniProt ID Q9NPH3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5125MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5089MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CAM-3001
GTTS-WQ9490MR IVTScrip™ mRNA-Anti-C5AR1, IPH-5401(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IPH-5401
GTTS-WQ8467MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HTI-1088
GTTS-WQ7255MR IVTScrip™ mRNA-Anti-STAB1, FP-1302(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA FP-1302
GTTS-WQ3800MR IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BAY-86-6150
GTTS-WQ12521MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA NPVPDR001
GTTS-WQ5308MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ1680MR IVTScrip™ mRNA-Anti-IL1B, ACZ885(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ACZ885
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW